Key result
This paper is a review discussing the opportunities and challenges involved in induced pluripotent stem cell-based therapies for inherited arrhythmias.
iPSC technology offers potential for modeling and treating inherited arrhythmias, but key challenges must be addressed before safe and efficient clinical use.
iPSC therapies for inherited arrhythmias require safety validation before clinical use; leaves open optimization of modeling and delivery.
The identification of induced pluripotent stem cell (iPSC) technology represents great potential for recapitulating complex physiological phenotypes, probing toxicological testing and screening candidate drugs, demonstrating novel mechanistic insights and, in particular, applying iPSC-based therapeutic strategies for inherited disorders. Inherited arrhythmias are caused by various genetic abnormalities and harbor similar clinical outcomes. Clinically, the poorest outcomes are fatal arrhythmias and sudden cardiac death. However, the current therapeutic options for inherited arrhythmias are inadequate and problematic. In this review, we summarize the advances of the iPSC technique in the field of inherited arrhythmias and discuss the possibility of iPSC‑based therapies for inherited arrhythmias. Additionally, we highlight the key challenges faced in the field of iPSC and the emerging strategies used to address these concerns before the novel technique can be used safely and efficiently in clinical practice. It is likely that the iPSC technique will present opportunities and further challenges in the future.
No takes yet. Share an insight, caveat, or question.
Li et al. (2014) conducted a review in Inherited arrhythmias. Induced pluripotent stem cell-based therapies was evaluated. This paper is a review discussing the opportunities and challenges involved in induced pluripotent stem cell-based therapies for inherited arrhythmias.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: